Yorgancioglu A.2024-07-222024-07-22201220406223http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/17814Bronchodilation is the cornerstone of chronic obstructive pulmonary disease (COPD) management and is based on regular treatment with one or more long-acting β2 agonists (LABAs). A novel bronchodilator, indacaterol, satisfies the requirements of an efficacious LABA: it has a relatively longer duration of action compared with existing LABAs and a fast onset of action. This review is a presentation of data on indacaterol with respect to its molecular characteristics as well as comparisons with other long-acting bronchodilators. Data from 12 relevant trials show that once-daily indacaterol provides significant, consistent and clinically important improvements in lung function (forced expiratory volume in 1 second), significant improvements in breathlessness and health status at least as good as or better than tiotropium, salmeterol and formoterol, and reduction in requirement for relief medication compared with tiotropium, salmeterol and formoterol. © 2012, SAGE Publications. All rights reserved.EnglishAll Open Access; Bronze Open Access; Green Open Accesscorticosteroidfluticasoneformoterolindacaterolplacebosalbutamolsalmeteroltiotropium bromidebinding affinitybronchodilatationbronchospasmcardiovascular diseasecerebrovascular diseasechronic obstructive lung diseaseclinical featurecoughingdisease exacerbationdose responsedrug absorptiondrug dose comparisondrug dose increasedrug effectdrug efficacydrug half lifedrug mechanismdrug potencydrug safetydrug structuredrug tolerabilitydrug withdrawaldyspneaforced expiratory volumeglucose blood levelheart diseaseheart infarctionhumaninfectioninfestationinspiratory capacitylipophilicitymediastinum diseasenonhumanoutcome assessmentpatient compliancepotassium blood levelpriority journalQT prolongationquality of liferespiratory tract diseasereviewrhinopharyngitisside effectsingle drug dosethorax diseasetime to maximum plasma concentrationtreatment durationIndacaterol in chronic obstructive pulmonary disease: An update for cliniciansReview10.1177/2040622311426204